SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The Melania crypto token continues to see intense community backlash as traders widely characterize it as a scam, fueling ongoing debate and heated criticism regarding its lack of utility. Investors are actively discussing the token's significant price decline and the broader pattern of political-themed meme coins that have faced similar allegations of being pump-and-dump schemes.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing heightened market attention driven by its critical role as the infrastructure layer for real-world asset tokenization and institutional financial integration. The community remains focused on potential regulatory tailwinds, such as the Clarity Act, while debating the long-term price correlation between its expanding utility as an oracle network and its token valuation.

Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Domestic Operations and International Operations segments. The company was founded on November 13, 2014 and is headquartered in Stamford, CT.

Curaleaf Holdings Inc

Curaleaf is in the spotlight following the announcement of a takeover bid for Aurora Cannabis, a move that has sparked community debate over potential synergies and valuation concerns. Investors are actively discussing the implications for sector-wide M&A trends as they weigh the company's international footprint and market leadership against ongoing regulatory and economic headwinds.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Immuneering Corp

Immuneering is currently trending as investors focus on its atebimetinib oncology platform, driven by compelling survival data in pancreatic cancer and anticipation surrounding upcoming data presentations at the ASCO annual meeting. Community discussions emphasize the company's favorable risk-reward profile and significant cash runway, while contrasting its valuation with larger peers in the space.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd. - ADR

Teva Pharmaceutical is trending as investors react to strong institutional accumulation and positive momentum following a favorable FDA filing for its once-monthly schizophrenia treatment. The community is actively discussing the stock's significant move toward 52-week highs, with bullish sentiment fueled by a successful pivot toward branded growth and expectations for continued valuation expansion.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently in the spotlight as investors speculate on the long-term potential of its oral drug candidate, soquelitinib, following positive analyst coverage and upcoming data presentations. While some community members are highlighting institutional accumulation and the potential for a short squeeze, others remain cautious due to the company's early-stage development and history of cash burn.

Lowe's Companies, Inc. engages in the retail sale of home improvement products. The firm offers products for maintenance, repair, remodeling, home decorating, and property maintenance. It also provides home improvement products in the following categories: appliances, seasonal & outdoor living, lumber, lawn & garden, kitchens & bath, hardware, building materials, millwork, paint, rough plumbing, tools, electrical, flooring, and décor. The company was founded in 1946 and is headquartered in Mooresville, NC.

Lowe`s Cos., Inc.

Lowe's Companies, Inc.

Lowe's shares are trending as investors weigh an earnings beat against broader home improvement sector pressures and cautious consumer spending trends. Community discussion remains focused on high-conviction institutional accumulation, potential technical breakout levels above the $220 mark, and the impact of the upcoming earnings release on near-term volatility.

Freddie Mac engages in the provision of housing finance system solutions. It operates through the Single-Family and Multifamily segments. The Single-Family segment is involved in purchase, securitization, and guarantee of single-family loans, investments, and management of single-family mortgage credit risk and market risk. The Multifamily segment focuses on purchase, securitization, and guarantee of multifamily loans, investments, securities, and management of multifamily mortgage credit risk and market risk. The company was founded on July 24, 1970 and is headquartered in McLean, VA.

Federal Home Loan Mortgage Corp

Freddie Mac

Freddie Mac (FMCC) and Fannie Mae (FNMA) are trending as investors analyze signals regarding their potential exit from government conservatorship, including recent leadership commentary, institutional activity, and the possibility of a taxpayer-backed IPO. The community remains heavily focused on the prospect of relisting on major exchanges, with many shareholders maintaining long-term positions while debating the timing of government policy shifts.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending as investors digest positive FDA news and analyze its market position for its lead IgA nephropathy drug, Trutakna. The community remains highly active, debating potential buyout scenarios and the drug's long-term competitive edge against other treatments in the sector.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate its long-term utility in digital payment infrastructure versus its ongoing price decline and management silence. While some community members are actively accumulating during this low-price period, others are vocalizing deep frustration over stagnant performance and questioning the project's transparency.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SOPH Stock Heads For Best Day In Over 8 Months – What’s Driving Today’s Super Rally?

Equity

Sophia Genetics announced a partnership with AstraZeneca to develop two cancer diagnostic tests and also raised its full-year revenue forecast.

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS Reports Second Quarter 2026 Results SOPHiA GENETICS Reports Second Quarter 2026 Results PR Newswire BOSTON and ROLLE, Switzerland, Aug. 4, 2026 BOSTON andROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine...

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies PR Newswire BOSTON and ROLLE, Switzerland, Aug. 4, 2026 BOSTON and ROLLE, Switzerland, Aug...

Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell?

TEM heads into Q2 earnings with 21.3% expected revenue growth, strong diagnostics demand and AI deals, but near-term margin pressure remains.

SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026

SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026 SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026 PR Newswire BOSTON and ROLLE, Switzerland, July 21, 2026 BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire...

SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting

SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting PR Newswire ROLLE, Switzerland, June 22, 2026 Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross...

SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares

SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to...

CarMax, Jabil And 3 Stocks To Watch Heading Into Wednesday

U.S. stock futures trading higher. CarMax, Sophia Genetics, Jabil, La-Z-Boy, and Safe Bulkers in focus. La-Z-Boy shares jump 17.7% after earnings.read more...

SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares

SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares PR Newswire BOSTON and ROLLE, Switzerland, June 16, 2026 BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA...

SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares

SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares PR Newswire BOSTON and ROLLE, Switzerland, June 16, 2026 BOSTONand ROLLE,Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global...

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

SOPHiA Genetics SA

Neutral Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

SOPHSOPHiA Genetics SA

Fundamentals

Connect Stocktwits to ChatGPT

Latest SOPH News